Brochure
27 May 2026

Analytical Services Overview

PDF 933 kB

Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides analytical services across the entire drug lifecycle. You can trust our analytical development and testing experts to rapidly advance your molecule for the greatest chance of success. Our analytical capabilities include:

  • Method development & validation
  • Material characterization
  • Compendial & release testing
  • Stability storage & testing
  • Biopharmaceutical testing
  • Microbiology & cleanroom services
  • Impurity isolation, identification & characterization
  • Reference standard qualification
Download our analytical capabilities and expertise overview brochure to learn more.

Content provided by our supplier

Cambrex

  • Country/Region:
    United States
  • Founded:
    1981
  • On CPHI since:
    2015
  • Certificates:
    4
  • Employees:
    1000 - 4999
Company types
Biopharmaceutical company
CMO/CDMO
Contract Service
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Analytical Services
API Producer
Biopharmaceutical
Chemical Development
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Intermediates Manufacturer
Laboratory Services
Pharmaceutical Company (generic finished products)

Other Content from Cambrex (10)

  • News Cambrex Expands Peptide Manufacturing Capabilities in Waltham, Massachusetts

    Cambrex announced today that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts to further support the development and manufacturing of peptide therapies.

  • Brochure Cambrex Capabilities Overview

    Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance, drug product, and analytical services across the entire drug lifecycle. As an innovative life sciences company with a refreshingly human approach to the way we do business, our pharmaceutical products, technologies and expertise help you accelerate your programs through development to market. Our core capabilities include:
    Drug substanceDrug productAnalytical testingTo see the full list of comprehensive services, download our company overview brochure.

  • News Cambrex Announces Cornell Professor Song Lin as Recipient of the 2025 Snapdragon Prize for Innovation in Chemistry Technology

    Cambrex and Snapdragon Chemistry, a Cambrex company, are proud to announce that Dr. Song Lin, Tisch University Professor in chemistry and chemical biology at Cornell University’s College of Arts and Sciences, has been awarded the 2025 Snapdragon Prize for Innovation in Chemistry Technology, which includes a $50,000 unrestricted fund for the Lin Lab.

  • News Cambrex Advances US and European Expansions

    Cambrex announced the completion of initial engineering studies for its new, large-scale active pharmaceutical ingredient (API) manufacturing plant in Charles City, Iowa. This milestone marks significant progress toward the company’s previously announced $120 million investment in expanding its U.S. API manufacturing capabilities. Groundbreaking for the new facility is scheduled to take place in late 2026.
  • Brochure Drug Substance Services

    From laboratory scale to commercial supply, you’ll enjoy working with our experts on your API. We have over 40 years of experience serving global clients with drug substance development and manufacturing needs for both custom and generic APIs and intermediates. Our robust services include:
    Custom API developmentCustom API manufacturingGeneric API manufacturingSolid state scienceMaterial characterizationWe specialize in complex programs utilizing innovative science and technology like continuous flow to solve complicated problems. We can also work with controlled substances and highly potent APIs. To learn more about our comprehensive drug substance capabilities, download our overview brochure.

  • News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company

    After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. 

  • Brochure Generic API and Intermediate Product List

    Cambrex is a leading global supplier of generic APIs. We work with generic drug companies well in advance of drug patent expiration, using high-quality, non-patent infringing processes to manufacture APIs. We produce over 90 generic APIs, intermediates, derivatives, and chiral compounds, including controlled substances.

    To see the complete list of the products we manufacture, download our full product list.

  • News CPHI North America 2023: from the experts - Cambrex

    Throughout CPHI North America (Philadelphia, PA; April 25–27, 2023), we caught up with some of the exhibiting organisations to ask what the show brings to the North American pharmaceutical sector, and what is driving industry innovation in this region of the world.    

  • Video A Different Brand of Experts

    Discover how Cambrex is shaping the future of pharmaceutical development in our latest video. At Cambrex, scientific innovation is at the heart of everything we do. We continually invest in advanced technologies—including biocatalysis, continuous flow technology, highly potent API manufacturing, reactor design and build, and more —to deliver transformative solutions for our partners and accelerate the path from development through commercialization. Our commitment to pushing the boundaries of what’s possible sets us apart as a leader in the industry.  Join us in celebrating innovation, collaboration, and the relentless pursuit of scientific advancement—watch now and see why Cambrex is your trusted partner in pharmaceutical development.
  • Video Expanded Peptide Capabilities in Waltham, Massachusetts

    Check out Snapdragon Chemistry’s new GMP manufacturing suite, which increases the overall facility footprint by 20% and includes an ISO-7 cleanroom for preparative HPLC chromatography and lyophilization, cold storage for raw materials and a product storage suite.